Structure Therapeutics, Inc. (GPCR)
16.90
-0.22
(-1.29%)
USD |
NASDAQ |
Nov 20, 10:10
Structure Therapeutics Cash from Operations (Quarterly) : -101.92M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -101.92M |
| June 30, 2026 | -120.38M |
| March 31, 2026 | 15.28M |
| December 31, 2025 | -64.69M |
| September 30, 2025 | -51.05M |
| June 30, 2025 | -54.75M |
| March 31, 2025 | -52.30M |
| December 31, 2024 | -36.44M |
| September 30, 2024 | -19.87M |
| June 30, 2024 | -26.37M |
| Date | Value |
|---|---|
| March 31, 2024 | -34.02M |
| December 31, 2023 | -21.91M |
| September 30, 2023 | -20.72M |
| June 30, 2023 | -16.61M |
| March 31, 2023 | -20.18M |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | -9.943M |
| March 31, 2022 | -13.46M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Eli Lilly & Co. | 11.40B |
| Novo Nordisk A/S | 6.389B |
| Merck & Co., Inc. | 6.558B |
| Prestige Consumer Healthcare, Inc. | 37.86M |
| Pfizer Inc. | 5.375B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 50.45M |
| Cash from Financing (Quarterly) | 0.7356M |
| Free Cash Flow | -278.01M |
| Free Cash Flow Per Share (Quarterly) | -1.449 |
| Free Cash Flow to Equity (Quarterly) | -106.17M |
| Free Cash Flow to Firm (Quarterly) | -105.57M |
| Free Cash Flow Yield | -23.05% |